486 related articles for article (PubMed ID: 19102711)
1. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
2. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
3. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
[TBL] [Abstract][Full Text] [Related]
4. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.
Llerena A; Dorado P; Ramírez R; González I; Alvarez M; Peñas-Lledó EM; Pérez B; Calzadilla LR
Pharmacogenomics J; 2012 Apr; 12(2):176-83. PubMed ID: 21135868
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.
Dorado P; Berecz R; Peñas-Lledó EM; Cáceres MC; Llerena A
Curr Drug Targets; 2006 Dec; 7(12):1671-80. PubMed ID: 17168842
[TBL] [Abstract][Full Text] [Related]
9. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.
Llerena A; Dorado P; Ramírez R; Calzadilla LR; Peñas-Lledó E; Álvarez M; Naranjo ME; González I; Pérez B;
Pharmacogenomics; 2013 Dec; 14(16):1973-7. PubMed ID: 24279852
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
Dalén P; Dahl M; Andersson K; Bertilsson L
Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
[TBL] [Abstract][Full Text] [Related]
12. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.
LLerena A; Berecz R; de la Rubia A; Dorado P
J Psychopharmacol; 2002 Dec; 16(4):361-4. PubMed ID: 12503836
[TBL] [Abstract][Full Text] [Related]
13. [Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].
Jarema M
Psychiatr Pol; 1995; 29(1):57-66. PubMed ID: 7878155
[TBL] [Abstract][Full Text] [Related]
14. [Prevalence of ultraextensive drug metabolizers in Croatian population--long-PCR based detection of amplified CYP2D6 gene].
Bozina N; Tramisak I; Granić P; Puljević D; Stavljenić-Rukavina A
Lijec Vjesn; 2002; 124(3-4):63-6. PubMed ID: 18958918
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
[TBL] [Abstract][Full Text] [Related]
16. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
17. The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.
Wink J; Veering BT; Kruit M; Burm AG; Huledal GA; Ekström GY; Stienstra R; van Kleef JW
Anesth Analg; 2008 Jan; 106(1):143-6, table of contents. PubMed ID: 18165569
[TBL] [Abstract][Full Text] [Related]
18. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
19. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.
Llerena A; Cobaleda J; Martínez C; Benítez J
Eur J Drug Metab Pharmacokinet; 1996; 21(2):129-38. PubMed ID: 8839686
[TBL] [Abstract][Full Text] [Related]
20. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.
González I; Peñas-Lledó EM; Pérez B; Dorado P; Alvarez M; LLerena A
Pharmacogenomics; 2008 Jul; 9(7):833-40. PubMed ID: 18597648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
